Melatonin receptors in pancreatic islets: good morning to a novel type 2 diabetes gene.
Level 5 - mechanism / opinion, no new human data
Narrative review of GWAS and mechanistic studies with no new data
PubMed 19377888 · doi:10.1007/s00125-009-1359-y
What was done
This narrative review synthesizes findings from three independent genome-wide association studies (GWAS) and physiological literature on melatonin receptors (MTNR1A and MTNR1B) in pancreatic islets and their contribution to type 2 diabetes risk.
What was found
The abstract reports no numerical values. It reports qualitatively that MTNR1B gene variants associate with hyperglycemia, impaired early-phase insulin secretion, and beta-cell dysfunction, and that risk genotype carriers have elevated MTNR1B expression in islets.
Why it matters
The paper highlights a molecular link between circadian hormonal regulation and glucose homeostasis, suggesting melatonin receptor pathways as potential targets for diabetes intervention.
Limits
No quantitative effect sizes, sample sizes, or formal meta-analytic methods are provided in the abstract. Evidence is based on narrative synthesis of association studies and mechanistic reasoning rather than direct clinical trial data.
Cited by
- supports Melatonin binding to its receptor on pancreatic cells inhibits insulin secretion.